FIGURE 13.

SPARC peptide 2.3 inhibits SPARC-induced ILK activity. SPARC-null LEC were treated with tunicamycin (24 h) in the presence of SPARC (0-13.5 nm) with and without SPARC peptides (1.1 or 2.3). Lysates were co-immunoprecipitated (IP) with rabbit anti-ILK antibodies and assayed for ILK activity. Relative expression of ILK in WT cells under each condition was normalized to the total amount of ILK protein immunoprecipitated for each reaction. Composite blots shown are from a single membrane and are representative of three independent experiments. Data were normalized to immunoprecipitated integrin ILK, and each column represents the mean of three independent experiments ±S.D. (^*, p < 0.05).